Armata Pharmaceuticals, Inc. (ARMP)

[timberwolf7]

all well and good, yes, some 'positives' for the company overall. BUT the basis for my comment still is:

-they haven't even started a clinical trial yet...

-they are looking at how many 'years' till they MIGHT get to the FDA for approval?

-to meet listing reqts, buyers are either going to have to step in and drive the price over a $/sh or a reverse split is going to happen

-my take is, has been, if a reverse split happens without a product about to be launched or at least close to being launched, its a set up for a take down in the share price.

especially with how long the company is looking at before they finish up just the phase 1 trial...

See, I don't like to overpay for something that is just getting started. 20 cents was my first trade of APHB, and a couple of others followed. This splits say 1-4 maybe 1-5 to hold its listing reqt of a $... Suspect with time, given where they are, some will say, overvalued cause they have NOTHING but a vision that still needs to be proven by at least the ph 1 (although I do agree, the 'expanded access' program shows it has promise)

So to close, it all comes down to how we each 'value' something... so while APHB or Amarata post merger will be in a 'better' position financially, it really doesn't mean a lot to me at this stage of the game.

Now if someone can post a 'timeline' for when they think a phase 3 is going to wrap up (or maybe they get away with just a ph 1 and 2 trial under the new FDA??), I may revise my viewpoint... course, it doesn't matter what I or you think, for the market will let us know what it thinks.. good luck